WASHINGTON, D.C. – Several diagnostics companies have received or will soon receive FDA Emergency Use Authorizations (EUA) that will provide crucial capacity for the U.S. to significantly ramp up testing for the coronavirus (COVID-19).
WASHINGTON, D.C. – FDA Commissioner Dr. Stephen Hahn joined a special meeting of AdvaMed’s Board of Directors today to discuss how the medical technology industry and FDA can continue their work together to ensure patients and health care providers have the medical equipment they need to address the COVID-19 pandemic.
WASHINGTON, D.C. – AdvaMed President and CEO Scott Whitaker and AdvaMedDx Executive Director Susan Van Meter issued the following statements upon introduction today in the House and Senate of the Verifying Accurate, Leading-edge IVCT Development (VALID) Act for regulatory oversight of in vitro clinical tests (IVCTs) – including in vitro diagnostics (IVDs) and laboratory-developed tests (LDTs):
WASHINGTON, D.C. – Since the onset of the coronavirus (COVID-19) outbreak, at least 31 AdvaMed member companies have donated medical products worth approximately $26.8 million and made cash donations worth $4.1 million to the China Red Cross Foundation and other medical institutions, such as hospitals and clinics in Hubei Province. Donations and the medtech community’s work will only grow in the coming weeks as the threat continues to elevate.
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) again urged the U.S. EPA to abandon its ethylene oxide (EtO) risk assessment value for one that is more feasible, based on the best available science and that will not potentially endanger the public health by threatening the availability of needed medical technologies.
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) this week urged the U.S. EPA to reassess its risk assessment value for ethylene oxide (EtO), arguing the threshold is neither practical nor is it based on the latest science, and pursuing it could pose an increased risk to public health through supply chain and distribution threats.
WASHINGTON, D.C. – This week, AdvaMed President and CEO, Scott Whitaker, and AdvaMed CFO and Executive Director of AdvaMed Advance, Jennifer Brearey, co-authored an editorial outlining steps the medical technology industry is taking to cultivate more diverse, more inclusive workplace cultures.
WASHINGTON and SAN DIEGO – February 10, 2020 – The Advanced Medical Technology Association (AdvaMed) and Biocom, the association representing the California life science industry, today announced a joint partnership to collaboratively produce The Digital MedTech Conference 2020. In combining Biocom’s DeviceFest and Digital Health Conference with AdvaMed’s Digital MedTech Conference, the single event will highlight the evolving digital medtech landscape and explore trends impacting the industry, all while bringing together key leaders from California and beyond. The conference will take place at the Millennium Biltmore Hotel in Los Angeles from May 19-20, 2020.
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement from President and CEO Scott Whitaker on the signing into law of the United States-Mexico-Canada Agreement (USMCA) by President Trump:
WASHINGTON, D.C. – Scott Whitaker, President and CEO of the Advanced Medical Technology Association (AdvaMed), issued the following statement on the emergence of the coronavirus: